No record found
No record found


* Returns not adjusted for payouts
Company Profile
Haleon Pakistan Limited (formerly known as GlaxoSmithKline Consumer Healthcare Pakistan Limited) was incorporated in Pakistan as a public listed company under the provisions of the repealed Companies Ordinance, 1984 (now Companies Act, 2017) on 31 March 2015. The Company is a subsidiary of ‘Haleon Netherlands B.V’. The ultimate parent of the Company is Haleon plc. The Company is inter alia principally engaged in the manufacturing, marketing and sale of consumer healthcare and over the counter health products.
Farhan Muhammad Haroon | CEO |
Sumru Atalay | Chairperson |
Mashal Mohammad | Company Secretary |
11-A, 11th Floor, Sky Tower (East Wing), Dolmen City, HC-3, Block 4, Scheme-5, Clifton, Karachi, 75600
CDC Share Registrar Services Limited CDC House, Main Shahrah-e-Faisal, Karachi.
M/s KPMG Taseer Hadi & Co. Chartered Accountants
December
Equity Profile
Announcements
Date | Title | Document |
---|---|---|
Feb 27, 2025 | Transmission of Annual Report for the Year Ended 2024 | View PDF |
Feb 7, 2025 | Additional Information to Financial Results for the Year Ended 31 December 2024 | View PDF |
Feb 6, 2025 | Financial Results for the Year Ended 31 December 2024 | View PDF |
Oct 30, 2024 | Transmission of Quarterly Report for the Period Ended 30 September 2024 | View PDF |
Oct 24, 2024 | Financial Results for the Period Ended 30 September 2024 | View PDF |
Aug 29, 2024 | Transmission of Half Yearly Report for the Period Ended 30 June 2024 | View PDF |
Aug 22, 2024 | Financial Results for the Quarter Ended 30 June 2024 | View PDF |
Apr 30, 2024 | Transmission of Quarterly Report for the Period Ended 31 March 2024 | View PDF |
Apr 25, 2024 | Financial Results for the Quarter Ended 31 March 2024 | View PDF |
Apr 8, 2024 | Transmission of Annual Report for the Year Ended 2023 | View PDF |
Date | Title | Document |
---|---|---|
Apr 18, 2025 | Notice of Board of Directors Meeting - (Q1-2025) | View PDF |
Mar 20, 2025 | CTC of Resolutions Passed in the Annual General Meeting 2024 | View PDF |
Feb 27, 2025 | Notice of Annual General Meeting | View PDF |
Feb 26, 2025 | Prior Publication of Annual General Meeting Notice | View PDF |
Jan 29, 2025 | Notice of Board of Directors Meeting - (Q4-2024) | View PDF |
Oct 16, 2024 | Notice of Board of Directors Meeting - (Q3-2024) | View PDF |
Aug 13, 2024 | Notice of Board of Directors Meeting - (Q2-2024) | View PDF |
Apr 26, 2024 | CTC of Resolutions Passed in the Annual General Meeting 2023 | View PDF |
Apr 17, 2024 | Notice of Board of Directors Meeting - (Q1-2024) | View PDF |
Apr 8, 2024 | Notice of Annual General Meeting | View PDF |
Apr 4, 2024 | Prior Publication of Annual General Meeting Notice | View PDF |
Date | Title | Document |
---|---|---|
Apr 17, 2025 | Material Information - Change of CEO | View PDF |
Mar 27, 2025 | Credit of Final Cash Dividend | View PDF |
Mar 26, 2025 | Prior Publication of Notice of Credit of Final Cash Dividend | View PDF |
Mar 21, 2025 | Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations | View PDF |
Mar 21, 2025 | (Re)Appointment of Chairperson and Chief Executive Officer | View PDF |
Mar 13, 2025 | Notice of Election of Directors | View PDF |
Mar 12, 2025 | Material Information Made in Pakistan Centrum First Export to Kenya | View PDF |
Mar 12, 2025 | Prior Publication of Notice of Election of Directors | View PDF |
Jan 15, 2025 | Notice of Change in UAN | View PDF |
Nov 20, 2024 | Presentation for Corporate Briefing Session 2024 | View PDF |
Nov 19, 2024 | Credit of Interim Cash Dividend | View PDF |
Financials
All numbers in thousands (000's) except EPS
2024 | 2023 | 2022 | 2021 | |
---|---|---|---|---|
Sales | 37,205,893 | 31,609,776 | 27,507,212 | 24,163,150 |
Profit after Taxation | 4,578,247 | 995,586 | 325,411 | 2,134,334 |
EPS | 39.11 | 8.51 | 2.78 | 18.23 |
Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | |
---|---|---|---|---|
Sales | 9,754,500 | 9,805,213 | 7,953,602 | 8,053,365 |
Profit after Taxation | 1,329,784 | 1,223,459 | 649,281 | 314,291 |
EPS | 11.36 | 10.45 | 5.55 | 2.68 |

Ratios
2024 | 2023 | 2022 | 2021 | |
---|---|---|---|---|
Gross Profit Margin (%) | 34.45 | 20.40 | 17.40 | 27.38 |
Net Profit Margin (%) | 12.31 | 3.15 | 1.18 | 8.83 |
EPS Growth (%) | 359.58 | 206.12 | (84.75) | 69.11 |
PEG | 0.06 | 0.10 | (0.70) | 0.19 |
Payouts
Date | Financial Results | Details | Book Closure |
---|---|---|---|
February 6, 2025 4:23 PM | 31/12/2024(YR) | 150%(F) (D) | 13/03/2025 - 20/03/2025 |
October 25, 2024 4:20 PM | 30/09/2024(IIIQ) | 50% (i) (D) | 07/11/2024 - 08/11/2024 |